Live
FierceBiotechArtivion nabs PMA clearance for aortic stent graft system, triggers Endospan buyout optionFierceBiotechWith $2B Novo deal in the books, Vivtex isn't 'limited to being just a drug delivery company': CEOFierceBiotechAstellas unearths Dyno muscle disorder AAV capsid with $15M option agreementFierceBiotechAkari locks arms with WuXi XDC to develop and manufacture novel ADC treatmentBioPharma DiveActivist investor revives campaign to overhaul Novavax boardEndpoints NewsMerck adjusts its vaccine supply deal in China; Soleno withdraws EU applicationBioPharma DiveJeito Capital, prominent biotech investor, raises $1.2B for next fundEndpoints NewsGilead takes another big swing at expanding beyond HIVIlluminaGrail seeks EU damages, costs over illegal veto on Illumina deal - MLexBioWorldSononeu wins $5.2M ARPA-H grant for ultrasound-activated therapeuticsEndpoints NewsInside the Talkspace-Universal Health Services dealLonza NewsImmuneOncia signs manufacturing agreement with Lonza for Danburstotug - Drug Discovery News
eLife Mar 10, 2026

<i>EPB41L4A-AS1</i> long noncoding RNA acts in both <i>cis</i>- and <i>trans</i>-acting transcriptional regulation and controls nucleolar biology

EPB41L4A-AS1 long noncoding RNA acts in both cis - and trans -acting transcriptional regulation and controls nucleolar biology

Original
Body unavailable. Use the original source.

Directory

59 All